• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides essentially stable vaccine compositions, as well as methods for their use and manufacture.
    公开号:BE1022254B1
    申请号:E2014/0589
    申请日:2014-08-01
    公开日:2016-03-04
    发明作者:Erin Weston；Krikor Torossian
    申请人:Glaxosmithkline Biologicals S.A.；
    IPC主号:
    专利说明:

    SACCHARID VACCINE FORMULATION Technical field
    The present invention relates to improved formulations for saccharide vaccines comprising immunogenic molecules of opposite charges.
    Background MAG-Tn3 is a glyco-peptidic antigen of approximately 11 kDa size. MAG-Tn3 is present in a substantial proportion in human cancers and is considered a candidate antigen for immunotherapy.
    For immunotherapy, MAG-Tn3 may be potentially combined with an immunostimulant. An example of an immunostimulant is a CpG oligodeoxynucleotide.
    In the manufacture of vaccines, a final liquid composition is produced containing one or more of the immunogenic molecules, commonly referred to as "final bulk". For storage facilities, the final bulk may be dried (for example, by lyophilization). The dried vaccine, sometimes referred to as the freeze-drying cake, may be reconstituted in a pharmaceutically acceptable solvent, such as water, a buffer, etc., and may be referred to as the "final container".
    A final bulk of MAG-Tn3 / CpG may be potentially freeze-dried to produce a final product for storage facilities. This final product may be potentially reconstituted in a buffer system or adjuvant system for administration to the patient.
    When formulating the molecules for vaccine use, it is not certain that the composition is stable. For example, the molecules may aggregate or precipitate under conventional conditions. Even if such problems are overcome, physical or chemical degradation of one or more components may occur. Compositions and methods that overcome such limitations are necessary. In addition, molecules that are stable when formulated alone can be coprecipitated in the presence of other molecules. Summary of the invention
    Substantially stable vaccine compositions are provided, the compositions comprising arginine; a counter-ion; a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge; the composition characterized in that when said composition comprises water (i) said first and second immunogenic molecules are substantially stable; and (ii) the pH of the resulting solution is less than 8.5. In some aspects, the first immunogenic molecule is Mag-Tn3. In some aspects, the second immunogenic molecule comprises a CpG oligonucleotide. In some aspects, a portion of the arginine is present as the arginine monohydrochloride species. In some aspects, the composition is dried. In some aspects, composition - includes water.
    In some aspects, the composition further comprises an adjuvant composition comprising one or both of the MPL and QS21 adjuvants. In some aspects, the adjuvant composition optionally further comprises liposomes.
    Methods of making substantially stable vaccine compositions are also provided, the methods comprising the steps of combining: arginine; a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge; wherein one or more of the foregoing components are combined with a liquid comprising water and wherein the pH of said composition is 8.5 or lower. Compositions produced by these methods are also provided.
    Methods of treating a patient are provided, the methods comprising the steps of administering a composition as described herein to a human. Uses are also proposed, in particular the use of arginine monohydrochloride as an additive in a substantially stable vaccine composition.
    Containers comprising the compositions as described herein are also provided.
    Brief description of the figures
    Figure 1 - Flowchart of the formulation procedure of CpG7909 and MAG-Tn3 mixed separately.
    Figure 2 - Flow chart of a classic formulation. The excipients used in the first step are listed in Table 2..
    Figure 3 - SDS-PAGE under reducing conditions of formulations of glutamic acid / lysine and glutamic acid / arginine and 1.0% w / v of Empigen after 24 hours at 4 ° C. MAG-Tn3 constitutes the main band at approximately 15 kDa. The arrows indicate the bands found in the fractions of the pellets, and the circles in dashed or dotted lines indicate the increase of the intensity of the band; the dotted lines being of greater intensity than the lines in points. The control in MAG-Tn3 PB was diluted in 10 mM succinate buffer pH 5.0, which was verified as the most stabilizing buffering system for MAG-Tn3 alone. This gel has been colored using SilverExpress. NC: non-centrifuged, SN: supernatant, P: resuspended pellet fraction, MM: molecular weight marker.
    Figure 4 - SDS-PAGE formulation of Tris-Maleate after 24 hours at 4 ° C. MAG-Tn3 constitutes the main band at approximately 15 kDa; the lower band corresponds to CpG at approximately 8 kDa. The arrows indicate the bands found in the fractions of the pellets, and the dots indicate the increase of the intensity of the band. The control in MAG-Tn3 PB was diluted in 10mM succinate buffer pH 5.0, which was verified as the most stabilizing buffering system for MAG-Tn3 alone. This gel has been colored using Silver Quest which colors CpG7909. NC: non-centrifuged, SN: supernatant, P: resuspended pellet fraction, MM: molecular weight marker.
    Figure 5 - SDS-PAGE under reducing conditions of an arginine and histidine formulation. MAG-Tn3 constitutes the main band at approximately 15 kDa; the lower band corresponds to CpG at approximately 8 kDa. The arrows indicate the bands found in the fractions of the pellets. NC: non-centrifuged, SN: supernatant, P: resuspended pellet fraction.
    Figure 6 - SDS-PAGE under reducing conditions of an L-arginine screening formulation. MAG-Tn3 constitutes the main band at approximately 15 kDa; the lower band corresponds to CpG at approximately 8 kDa. NC: non-centrifuged, SN: supernatant, P: resuspended pellet fraction. A slightly more intense band (encircled) is observed in the pellet fraction of the 15 mM L-arginine formulation, compared to the other formulations.
    Figure 7 - HPLC-SEC fluorescence chromatographic overlay of L-arginine formulations of 15 to 35 mM.
    Figure 8 - SDS-PAGE under reducing conditions of a L-arginine monohydrochloride screening formulation. MAG-Tn3 constitutes the main band at approximately 15 kDa; the lower band corresponds to CpG at approximately 8 kDa. NC: non-centrifuged, SN: supernatant, P: resuspended pellet fraction. Slightly more intense bands in the pelleted fractions were observed from 225 mM to 300 mM Larginine monohydrochloride, encircled.
    Figure 9 - HPLC-SEC fluorescence chromatographic overlay of 100-200 mM L-arginine monohydrochloride formulations.
    Figure 10 - SDS-PAGE under reducing conditions of dose range formulations. MAG-Tn3 constitutes the main band at approximately 15 kDa; the lower band corresponds to CpG at approximately 8 kDa. The arrow indicates a slight band in the pellet fraction of the highest concentration of MAG-Tn3. NC: non-centrifuged, SN: supernatant, P: resuspended pellet fraction. Control in the purified bulk of MAG-Tn3 was loaded into wells 2 to 4.
    Figure 11 - Chromatographic overlay of size exclusion profiles of MAG-Tn3 formulations from 200 to 900 μq / ml.
    Figure 12 - SDS-PAGE under reducing conditions of dose range formulations. MAG-Tn3 constitutes the main band at approximately 15 kDa; the lower band corresponds to CpG at approximately 8 kDa. The arrow indicates a slight band in the pelleted fractions of the higher concentrations of MAG-Tn3. The higher molecular weight bands present in well 18 are abnormal. NC: non-centrifuged, SN: supernatant, P: resuspended pellet fraction.
    Figure 13 - Superposition of HPLC-SEC chromatograms of 420, 270 and 180 μg of CpG7909 / dose of standard end containers at T0.
    Figure 14 - HPLC-SEC overlay of 420 μρ of CpG7909 / dose of MAG-Tn3 formulation at T0, 4 and 24 hours incubation at 25 ° C.
    Figure 15 - Superposition of the HPLC-SEC chromatograms of 180, 270 and 420 μρ of CpG7909 / dose of the MAG-Tn3 formulations after a 24 hour incubation at 25 ° C.
    detailed description
    Applicants have discovered that the combination of MAG-Tn3 and CpG molecules in solution causes instant coprecipitation and that when a freeze-dried dry cake was reconstituted, it was not soluble using conventional excipients.
    The inventors have surprisingly found that the inclusion of arginine, including an arginine monohydrochloride species fraction, in a formulation for use with a first immunogenic molecule having a net positive charge, in combination with a second immunogenic molecule having a net negative charge, allows an appropriate combination of stability and pH for use in the form of an injectable vaccine in mammalian subjects.
    Compositions comprising arginine
    In some aspects, the description provides vaccine compositions comprising arginine, a counterion, a first immunogenic molecule having a net positive charge, and a second immunogenic molecule having a net negative charge, the composition being characterized in that when said composition comprises a pharmaceutically acceptable solvent (i) said first immunogenic molecule and said second immunogenic molecule are substantially stable; and (ii) the pH is less than 8.5.
    In some aspects, the first immunogenic molecule comprises a carbohydrate group. In some aspects, the first immunogenic molecule comprises a Tn group. In some aspects, the first immunogenic molecule comprises MAG-Tn3.
    In some aspects, the second immunogenic molecule comprises an oligonucleotide. In some aspects, the oligonucleotide is an immunostimulatory oligonucleotide. In some aspects, the oligonucleotide is an oligonucleotide containing CpG. In some aspects, the oligonucleotide is CpG7909.
    Arginine Arginine may be present in L or D forms, or a mixture of both. L-arginine is also known as 2-amino-5-guanidino-valeric acid; 2-amino-5-guanidinovalerate; L-α-Amino-d-guanidino valerate; L-alpha-Amino-delta-guanidino-valeric acid; L-α-Amino-d-guanidinovaleric acid; N5- (aminoiminomethyl) -L-alpha-OrnithineL
    Amino-delta-guanidino-valerate; 5- [(aminoiminomethyl) amino] -L-Norvaline (S) -2-Amino-5 - [(aminoiminomethyl) amino] pentanoic acid; (S) -2-amino-5- [(aminoiminomethyl) amino] pentanoate; (S) -2-Amino-5 - [(amino iminomethyl) amino] pentanoate; and (S) -2-amino-5 - [(aminoiminomethyl) amino] -pentanoic acid. Arginine is represented by formula I:
    Formula I Arginine can be neutralized with hydrochloric acid or acids having a conjugate base other than chlorides, producing Arginine · Η-Χ, where X includes without limitation Ci ", SO4" 2, and citrate.
    In some aspects, the arginine species includes arginine monohydrochloride.
    The arginine monohydrochloride may be present in L or D forms, or a mixture of both. It is also known as (2S) -2-Amino-5 - [(aminoiminomethyl) amino] pentanoic acid hydrochloride, arginine hydrochloride, and arginine · HCl. Arginine monohydrochloride can be manufactured by neutralizing arginine with hydrochloric acid. Arginine monohydrochloride is represented by formula II.
    Formula II Arginine and arginine HCl are used in cell culture media and drug development. The amino acid arginine is used in the form of a solution additive to stabilize proteins against protein-protein aggregation, especially in the protein folding process. See Baynes et al. (2005) Biochemistry 44: 4919-4925; Tsumoto et al. (2004) Biotechnol. Prog. 20: 1301-1308. As explained in Baynes, aggregation is the assembly of conformations of non-native proteins into multimer states, often leading to phase separation and precipitation. The presence of arginine in solution has been shown to slow down protein-protein association reactions in two model systems: the combination of insulin with a monoclonal antibody and the combination of folding intermediates and aggregates carbonic anhydrase II (CA). Arginine has been used as a replacement for human serum albumin to protect therapeutic proteins, including glycoproteins, from degradation. See Kim (2009) Biosci Biotechnol Biochem. 73: 61-6.
    Because arginine in solution is a polyprotic / base acid system, it is associated with four different states of protonation / charge. An arginine solution will include a mixture of species having different states of protonation. These states are: 1. "H3B2 +",
    Formula III
    When the counterion is 2 Cl-, the protonation state of formula III is known as arginine dihydrochloride. 2. "H2B +",
    Form IV
    When the counterion is Cl-, the protonation state of formula IV is known as arginine monohydrochloride, or arginine »HCl. 3. "HB"
    Formula V The protonation state of formula V is known as arginine base. 4. "B"
    Form VI
    When the counterion is Na + or K +, the protonation state of formula VI is known as sodium or potassium arginate.
    The protonation / deprotonation of arginine proceeds according to the following scheme.
    Scheme I
    ## EQU1 ##, ## STR2 ##
    IV V VI
    By "immunogenic molecule" is meant a molecule capable of inducing an immune response in a subject.
    The term "molecules" herein includes without limitation macromolecules, oligomer molecules, and monomers. By "macromolecule" is meant polymeric molecules of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, conceptually or conceptually, from molecules of low relative molecular mass, including polysaccharides, polypeptides, nucleic acids, and the like, as well as non-polymeric molecules with a large molecular weight such as lipids and macrocycles. By "oligomer molecule" is meant a molecule of intermediate relative molecular weight, the structure of which essentially comprises a small plurality of units derived, conceptually or conceptually, from molecules of lower relative molecular mass. By "monomer" is meant a molecule that can undergo polymerization.
    By "net charge" of a molecule is meant the arithmetic sum of the positive and negative charges on the molecule at a given pH or in a given pH range. A molecule with a "net positive charge" will have a majority of positive charges at a given pH or within a given pH range; in the same way, a molecule with a "net negative charge" will have a majority of negative charges at a given pH or in a given pH range. The pH or pH range applicable is the pH or pH range of the solution comprising the relevant molecule.
    Carbohydrate groups comprising a group Tn
    In some aspects, the description provides immunogenic molecules comprising carbohydrate groups or carbohydrate antigens.
    By "carbohydrate group" is meant a carbohydrate moiety of a molecule chemically linked to another part of the molecule. Thus, a carbohydrate group can be attached to another carbohydrate molecule or another class of molecule, such as a protein (or a peptide). Examples of molecules having carbohydrate groups include oligosaccharides, polysaccharides, glycopeptides, glycoproteins, and the like, some of which may be carbohydrate antigens.
    By "carbohydrate antigen" is meant a saccharide antigen, including bacterial capsular polysaccharides, tumor associated carbohydrate antigens, and the like.
    In some aspects, the description provides immunogenic molecules comprising a Tn group.
    By "Tn" or "Tn group" is meant a member of the glycophorin family as described in Morrelli (2011) Eur. J. Org. Chem. 5723-5777. Tn can be described as an N-acetylgalactosamine bound to either a serine or threonine residue via a glycosidic bond.
    Thus, a molecule comprising Tn will have one or more Tn groups.
    In some aspects, the description provides immunogenic molecules comprising MAG-Tn3. "MAG-Tn3" is described in EP2500033A1 and has the following structure:
    MAG-Tn3 Formula VII
    Thus, MAG-Tn3 corresponds to a B4-T4-M peptide carbohydrate conjugate of formula VIII:
    Formula VIII in which - KKK represents the dendritic polyLysine nucleus (M),
    T represents the peptide epitope of CD4 + T lymphocytes having the following sequence: QYIKANSKFIGITEL - Tn3 represents the tri-Tn epitope of B lymphocytes having the following sequence: (α-GalNAc) Ser- (α-GalNAc) Thr- (a -
    GalNAc) Thr. MAG-Tn3 has an estimated pI of 9.8 to 10, and is therefore very positively charged at neutral pH.
    oligonucleotides
    By "immunostimulatory oligonucleotide" is meant an oligonucleotide which comprises an immunostimulatory DNA motif. Immunostimulatory DNA motifs are described in Sato et al. (1996) Science 273: 352. Examples of immunostimulatory oligonucleotides include oligonucleotides containing CpG (in which the CpG dinucleotide is unmethylated), which induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and US Pat. Nos. 6,008,200 and 5,856,462.
    Examples of oligonucleotides containing CpG include the following specific sequences:
    CpG7909 is a synthetic 24-mer single-stranded oligodeoxynucleotide with a phosphorothioate backbone of approximately 8 kDa and has 23 negative charges at neutral pH.
    The term "essentially stable" is meant to describe a solution in which the solute does not precipitate in the solution. That is, once a limited period of time has passed after the solute of interest has dissolved in the solution, T1, more than 70% of the solute will remain in solution, that is, ie, more than 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93 , 94, 95, 96, 97, 98, 99% or more of the solute will remain in solution.
    The limited period of time, T1, may be any period of time greater than 1 hour, that is, 1, 2, 3, 5, 10, 20, 50, 75, 100, 150, 200, 250 , 500, 750, 1000, 1500 hours or more.
    Stability can be estimated by many methods, including, for example, the measurement of loss after filtration, the determination of the presence of the solute of interest in a pellet fraction (by SDS-PAGE or an equivalent method) or by determining the aggregation profile for the solute of interest.
    In some aspects, the composition is characterized in that when the composition comprises water, the pH of the composition is within a range where the upper pH limit is less than 8.5; less than 8.4; less than 8.3; less than 8.2; less than 8.1; less than 8.0; less than 7.9; less than 7.8; less than 7.7; less than 7.6; or less than 7.5 and the lower limit is greater than 7.4; greater than 7.5; greater than 7.6; greater than 7.7; greater than 7.8; greater than 7.9; greater than 8.0; greater than 8.1; greater than 8.2; greater than 8.3; or greater than 8.4. In some aspects, the pH is between 7.4 and 8.5, inclusive; between 7.5 and 8.5, inclusive; between 7.6 and 8.3, inclusive; between 7.7 and 8.3, inclusive; between 7.8 and 8.3, inclusive; between 7.9 and 8.3, inclusive; between 8.0 and 8.3, inclusive; between 8.1 and 8.3, inclusive.
    Methods for obtaining the desired pH of the composition include neutralizing the arginine solution with a suitable acid, such as hydrochloric acid, or the combination of a necessary amount of arginine and arginine · HX to produce the desired pH in the solution. In some aspects, arginine arginine monohydrochloride is the arginine · Η-Χ. The arginine / arginine monohydrochloride ratio required to produce a desired pH can be easily calculated using known methods, such as the Henderson-Hasselbalch equation, in which pH = pKa + log ([Arg deprotonated] / [rotonated Arg] ) Equation 1.
    For example, Table 1 indicates the calculated pH resulting from various molar ratios of arginine / arginine-HCl.
    Table 1. pH values calculated using Equation 1 for solutions comprising various Arg / Arg-HCl molar ratios (pKa Arg = 8.991).
    As will be understood, the true pH of the solutions produced can be confirmed and adjusted by means of
    routine, like a pH meter. In some aspects, the true pH is not more than ± 0.2 pH units of the calculated pH value or not more than ± 0.2 pH units outside the calculated pH range. .
    In some aspects, the composition is characterized in that when said composition comprises water, the arginine comprises the following species: (a)
    Formula V and (b)
    Form IV.
    In some aspects, the molar ratio of species (a) to species (b) is between 7/220 (0.032) and 71/220 (0.323). In some aspects, the molar ratio of species (a) to species (b) is between 1/11 (0.091) and 1/5 (0.200). In some aspects, the formula V is at least 14 mM, and the molar ratio of the species of (a) Formula V to the species of (b) Formula IV is within a range chosen in the group consisting of: (a) between 0.091 and 0.200; (b) between 0.032 and 0.323; (c) between 0.041 and 0.323; (d) between 0.051 and 0.256; (e) between 0.064 and 0.256; and (f) between 0.081 and 0.204.
    cryoprotectants
    In some aspects, the composition comprises a cryoprotectant.
    By "cryoprotectant" is meant a substance used to protect biomolecules against freezing conditions, such as those encountered during freeze drying or lyophilization. Examples of cryoprotectants include carbohydrates, such as saccharide sucrose, sugar alcohols such as mannitol, surfactants such as polysorbates, as well as glycerol and dimethyl sulfoxide. Examples of carbohydrates include saccharides and disaccharides. Examples of disaccharides include sucrose and trehalose.
    Adj uants
    In some aspects, the compositions and methods also include an adjuvant composition comprising one or more adjuvants. In the context of an immunogenic composition suitable for administration to a subject, such as a human subject, for the purpose of eliciting an immune response, the adjuvant composition is selected to elicit a Th1-responsive immune response. The adjuvant composition is generally chosen to enhance a Th1-responsive immune response in the subject, or subject population, to which the composition is administered.
    A "Thl" type immune response is characterized by the induction of CD4 + helper T cells that produce IL-2 and IFN-γ. In contrast, a "Th2" type immune response is characterized by the induction of CD4 + helper cells that produce IL-4, IL-5, and IL-13.
    Modulators of TLR4
    A suitable adjuvant is a TLR4 modulator. An example is a non-toxic derivative of lipid A, monophosphoryl lipid A or more particularly, monophosphoryl lipid A 3-deacylated (3D-MPL). 3D-MPL is sold as MPL by GlaxoSmithKline Biologicals N.A., and is cited throughout the document as MPL or 3D-MPL. See, for example, U.S. Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094. 3D-MPL primarily promotes CD4 + T cell responses with an IFN-γ (Th1) phenotype. 3D-MPL can be produced according to the methods described in GB2220211 A. From the chemical point of view, it is a mixture of monophosphoryl-lipid A 3-deacylated with 3, 4, 5 or 6 acylated chains. In the compositions of the present invention, small particle 3D-MPL may be used. The small particle 3D-MPL has a particle size such that it can be sterilized by filtration through a 0.22 μπι filter. Such preparations are described in WO94 / 21292.
    In other embodiments, the lipopolysaccharide may be a disaccharide of β (1-6) glucosamine, as described in US Patent No. 6,005,099 and EP Patent No. 0,729,473 B1. The art can easily produce various lipopolysaccharides, such as 3D-MPL, based on the teachings of these references. Nevertheless, each of these references is incorporated herein by reference. In addition to the aforementioned immunostimulants (which are structurally similar to that of LPS or MPL or 3D-MPL), acylated derivatives of monosaccharides and disaccharides which form a subpart of the above structure of MPL are also appropriate adjuvants. In other embodiments, the adjuvant is a synthetic derivative of lipid A, some of which are described as TLR-4 agonists, and include, but are not limited to: OM174 (2-deoxy-6-o) - [2-deoxy-2 - [(R) -3-dodécanoyloxytétra-decanoylamino] -4-o-phosphono-ß-D-glucopyranosyl] -2 - [(R) -3-hydroxytetradecanoyl-amino] -ad-glucopyranosyldihydrogénophosphate ), (WO 95/14026); OM 294 DP (3S, 9R) -3 - [(R) -Dodecanoyloxytetradanoylamino] -4-oxo-5-aza-9 (R) - [(R) -3-hydroxytetradecanoyl-amino] decane-1.10 diol, 1,10-bis (dihydrogenphosphate) (WO 99/64301 and WO 00/0462); and OM 197 MP-Ac DP (3S, 9R) -3 - [(R) -Dodecanoyloxytetradecanoylamino] -4-oxo-5-aza-9 - [(R) -3-hydroxytetradecanoylamino] decane-1,10-diol, 1-dihydrogen phosphate 10- (6-aminohexanoate) (WO 01/46127).
    Saponin Adjuvants Other adjuvants that can be used in immunogenic compositions herein, for example, by themselves or in combination with 3D-MPL, or another adjuvant described herein, are saponins, such as QS21.
    Saponins are described in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins, Phytomedicine vol 2 pp 363-386). Saponins are steroidal or triterpenic glycosides widely distributed in the plant kingdom and the reign of marine animals. Saponins are known to form colloidal solutions in water that foam during agitation, and to precipitate cholesterol. When saponins are close to cell membranes, they create pore-like structures in the membrane that cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of some, but not all, saponins. '
    Saponins are known as adjuvants in vaccines for systemic administration. The adjuvant and haemolytic activity of individual saponins has been intensively studied in the art (Lacaille-Dubois and Wagner, above). For example, Quil A (derived from the bark of the South American tree Quillaja Saponaria Molina), and its fractions, are described in US 5,057,540 and "Saponins as vaccine adjuvants", Kensil, CR, Crit Rev Ther Drug Carrier Syst, 1996, 12 (1-2): 1-55; and EP 0 362 279 B1. Particulate structures, termed immunostimulatory complexes (ISCOMs), comprising quil A moieties are hemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 B1; WO 96: 9711; WO 96/33739). The hemolytic saponins QS21 and QS17 (Quil A HPLC purified fractions) have been described as potent systemic adjuvants, and their method of production is disclosed in US Patent No. 5,057,540 and EP 0 362 279 B1, which are incorporated herein by reference. Other saponins that have been used in systemic vaccination studies include those derived from other plant species such as Gypsophila and Saponaria (Bomford et al., Vaccine, 10 (9): 572-577, 1992).
    Such formulations comprising QS21 and cholesterol have been shown to be effective adjuvants stimulating the Th1 response when formulated together with an antigen.
    Other molecules
    In some aspects, one or more other molecules may be included in the compositions, including nonionic surfactants and emulsifiers, such as polysorbate 80 (Tween ™ 80, available from ICI Americas, Inc.), excipients, buffers, and the like, such as sodium phosphate, potassium phosphate, etc.
    liquids
    In some aspects, the compositions according to the invention comprise water. In some aspects, arginine is present at a concentration of at least 15 mM, i.e., 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40 mM, or greater. In some aspects, arginine monohydrochloride is present at a concentration of at least 45 mM, i.e., 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100. , 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225 , 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300 mM, or greater.
    Final bulk
    In some aspects, the composition comprises water and the first immunogenic molecule comprises MAG-Tn3 and is present at a concentration of less than or equal to 900 μg / ml. In some aspects, the composition comprises water and the first immunogenic molecule comprises MAG-Tn3 and is present at a concentration between 60 and 900 μρ / πιΐ inclusive. In some aspects, the composition comprises water and the oligonucleotide is present at a concentration of less than 1140 μρ / ml. In some aspects, the composition comprises water and the oligonucleotide is present at a concentration of 760 to 1140 μΐ / ml, inclusive. In some aspects, the composition comprises water and the oligonucleotide is present at a concentration of 950 μρ / ml. In some aspects, the composition comprises water and arginine is present at a concentration of 25 mM. In some aspects, the composition comprises water and the arginine monohydrochloride is present at a concentration of 187.5 mM. In some aspects, the composition comprises water and (i) between 60 and 900 μρ / ml MAG-Tn3, inclusive; (ii) 950 μg / ml of CpG 7909 (SEQ ID NO: 4); (iii) 25 mM arginine; (iv) 187.5 mM arginine monohydrochloride; (v) 0.108% w / v of
    Polysorbate 80; and (vi) 5% w / v sucrose. Dried cake
    In some aspects, the composition is dried, and the arginine / arginine monohydrochloride ratio is 20/150 (mol / mol) or 1.74 / 15.8 (w / w). In some aspects, the dried composition comprises between 380 and 570 μρ of CpG 7909 (SEQ ID NO: 4). In some aspects, the dried composition comprises (i) between 30 and 450 μq of MAG-Tn3, inclusive; (ii) 475 μρ of CpG 7909 (SEQ ID NO: 4); (iii) 0.87 mg arginine; (iv) 7.9 mg arginine monohydrochloride; (v) 0.216 mg Polysorbate 80; and (vi) 10 mg of sucrose. Final container
    In some aspects, the composition comprises water and the first immunogenic molecule comprises MAG-Tn3 and is present at a concentration of less than 720 μρ / ml. In some aspects, the composition comprises water and the first immunogenic molecule comprises MAG-Tn3 and is present at a concentration between 48 and 720 μg / ml, inclusive. In some aspects, the composition comprises water and the oligonucleotide is present at a concentration of from 608 to 912 μg / ml. In some aspects, the composition comprises water and the oligonucleotide is present at a concentration of 760 μρ / ιηΐ. In some aspects, the composition comprises water and arginine is present at a concentration of 20 mM. In some aspects, the composition comprises water and arginine monohydrochloride is present at a concentration of 150 mM. In some aspects, the composition comprises water and (i) between 48 and 720 μρ / ml MAG-Tn3, inclusive; (ii) 760 μg / ml of CpG 7909 (SEQ ID NO: 4); (iii) 20 mM arginine; (iv) 150 mM arginine monohydrochloride; (v) 0.0864% w / v Polysorbate 80; and (vi) 4% w / v sucrose. In some aspects, the composition comprises water and (i) between 48 and 720 μρ / πιΐ of MAG-Tn3, inclusive; (ii) 760 μρ / ιηΐ of CpG 7909 (SEQ ID NO: 4); (iii) 20 mM arginine; (iv) 150 mM arginine monohydrochloride; (v) 0.0864% w / v Polysorbate 80; and (vi) 4% w / v sucrose; (vii) 150 mM NaCl; (viii) 8mM KH2PO4 and 2mM Na2HPO4; (ix) 50 μl / ml of MPL; (x) 100 μρ / ml of liposomes; and (xi) 100 μρ / ml of QS21.
    Processes and methods
    In some aspects, there are provided herein methods of making essentially stable vaccine compositions, comprising combining their components in a single step, or in several steps. In some aspects, there are provided herein methods of making essentially stable vaccine compositions comprising a step of combining the arginine-comprising components; a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge. In some aspects, there are provided herein methods of making essentially stable vaccine compositions comprising the steps of combining the arginine-comprising components; a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge. In some aspects, arginine may include a species having a counterion. In some aspects, there are provided methods of making substantially stable vaccine compositions comprising a step of combining the arginine-comprising components; arginine monohydrochloride; a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge. In some aspects, there are provided methods of making essentially stable vaccine compositions comprising the steps of combining the arginine-comprising components; arginine monohydrochloride; a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge. In some aspects, there are provided methods of making substantially stable vaccine compositions comprising the steps of combining the arginine components; arginine monohydrochloride; a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge. One or more of these components are combined with a liquid comprising water. Conventional methods can be used to combine these components. In general, a stock solution comprising arginine and the arginine monohydrochloride species is prepared, which is then combined with stock solutions of the other components. Alternatively, arginine monohydrochloride can be prepared by neutralizing arginine with hydrochloric acid. When a different counterion is desired, it is possible to use similar approaches that use a different acid.
    For example, when the immunogenic molecules are MAG-Tn3 and CpG, respectively, the following formulation protocol can be followed: using stock solutions of 500 mM L-arginine and 1 M Larginine monohydrochloride, formulations can be constituted by adding 31.3 mM L-arginine and 187.5 mM L-arginine monohydrochloride to a 5% sucrose solution in water for injection (available from Thermo-Fisher). MAG-Tn3 and CpG are both commercially available and the manufacturer's protocol for the preparation of stock solutions of these molecules can be followed. CpG7909 (available from Agilent) is then added to the solution at a concentration of 1050 μρ / ιηΐ. The solution is then stirred magnetically for 5 minutes at 150 rpm. MAG-Tn3 obtained from Lonza Braine is then added to the solutions at concentrations in the range of 250 to 1125 μg / ml. The solutions are then stirred magnetically for a further 5 minutes at 150 rpm. The formulations are then diluted 1.25 times in a solution of 50 mM Na 2 HPO 4 / KH 2 PO 4, 150 mM NaCl pH 6.1. See examples 3 and 4.
    In some aspects, there are provided methods of drying the composition. Conventional techniques can be used to dry the composition, including freeze-drying, lyophilization, and the like. Conventional freeze-drying protocols can be used. In one aspect, a 64-hour lyophilization cycle is used wherein a product temperature below -34.5 ° C is avoided during the primary drying phase of the freeze cycle. For example, the conditions may include initial freezing for 1 hour at -52 ° C, followed by primary drying where the temperature is increased between -27 ° C and -37 ° C in 2.5 to 3.5 hours. The temperature can then be maintained for approximately 27 to 37 hours. The temperature of the primary drying can then be gradually increased between -23 ° C and -33 ° C over a period of 4.25 to 5.75 hours. This temperature can be maintained for 4.25 to 5.75 hours. All primary drying can be done with a chamber pressure of 45 pbar (34 mTorr). The secondary drying can start with the temperature gradually increased between 32 and 42 ° C in 5.4 to 6.6 hours at a chamber pressure of 15 to 75 pbar (11 to 56 mTorr) and maintained for 10.8 to 13.2 hours at a pressure of 10 to 45 pbar (8 to 34 mTorr).
    In some aspects, there are provided methods for combining the compositions with a liquid comprising water, wherein the liquid further comprises an adjuvant composition comprising one or more adjuvants, wherein at least one of the adjuvants is selected in the group consisting of MPL and QS21. In some aspects, there are provided methods for reconstituting the dried compositions, comprising the steps of combining the dried composition with a liquid comprising water, wherein the liquid further comprises an adjuvant composition comprising one or more adjuvants selected from the group consisting of MPL and QS21. In some aspects, the adjuvant further comprises liposomes.
    In some aspects, products are proposed according to the preceding methods.
    In some aspects, the compositions may be present in one or more containers. For example, a first container may comprise arginine and the first and second immunogenic molecules, while a second container may comprise an adjuvant composition comprising one or more adjuvants selected from the group consisting of MPL and QS21. Alternatively, a container may comprise arginine, the first and second immunogenic molecules, and an adjuvant composition comprising one or more adjuvants selected from the group consisting of MPL and QS21. In some aspects, kits comprising one or more containers comprising the compositions are provided.
    In some aspects, there are provided methods of treating a patient comprising the steps of administering a composition described herein. In some aspects, there are provided methods of inducing an immunogenic response comprising the steps of administering a composition to a human. Administration can be by injection.
    In some aspects, the use of arginine monohydrochloride as an additive for stabilizing a vaccine composition is proposed.
    In some aspects, the compositions provided herein are for use in medicine, as for use in inducing an immune response. In some aspects, the compositions are for use in the treatment of cancer, where the first immunogenic molecule is Mag-Tn3. In some aspects, the compositions are for use in the treatment of breast cancer, where the first immunogenic molecule is Mag-Tn3.
    Unless otherwise indicated, all technical and scientific terms used herein have the same meaning as commonly understood by a person of average skill in the field to which this invention belongs. The terms singular "one", "one", "the" and "the" include plural articles unless the context clearly indicates otherwise. Similarly, the word "or" is meant to include "and" unless the context clearly indicates otherwise. The term "plurality" refers to two or more. In addition, the numerical limitations given with respect to the concentrations or levels of a substance, such as the concentrations of the components in the solutions or their ratios, and the reaction conditions such as temperatures, pressures and cycle times are supposed to be approximate . Thus, when a pH is indicated as being at least pH 7.5, it is expected that the pH will be understood to be at least approximately (or "about" or "~") pH 7.5, i.e. ie, at least 7.5 ± 0.2 pH units. The invention will be further described with reference to the figures and non-limiting examples which follow.
    Examples
    EXAMPLE 1 Screening of Excipients: Determination of a Buffer System Suitable for Mag-Tn3 and CpG7909
    The target dose for MAG-Tn3 antigen was set at 500 μg / dose. In the presence of immunostimulant CpG7909, MAG-Tn3 antigen instantly coprecipitates. A multitude of buffer systems have been tried in an effort to solubilize this antigen-immunostimulatory combination. This report will detail the many combinations of buffers and excipients tested in an attempt to solubilize MAG-Tn3 and CpG7909. MAG-Tn3 is a glycopeptide antigen of approximately 11 kDa size. It has an estimated pI of 9.8 to 10, and is therefore very positively charged at neutral pH. This antigen must be combined with the immunostimulant CpG7909 to be formulated as a freeze-dried vaccine which will have to be reconstituted in the adjuvant system known as AS01B. CpG7909 is a synthetic 24-mer single-stranded oligodeoxynucleotide with a phosphorothioate backbone of approximately 8 kDa and has 23 negative charges at neutral pH. The combination of these two molecules without the addition of excipients causes instant coprecipitation.
    Initial attempts to solubilize MAG-Tn3 and CpG7909 were performed at the final bulk level, where compatibility with the AS01B buffer system was not estimated. These experiments indicated that with the addition of histidine at a concentration of 18.75 mM in the final bulk, a soluble formulation was obtained. When this final lyophilized product was reconstituted in the adjuvant buffer system, it was found that the formulation was no longer soluble and that the coprecipitation problem had not been fully resolved. The purpose of the experiments described in this report was to find a way by which both MAG-Tn3 and CpG7909 could be formulated together in a soluble vaccine formulation upon reconstitution in AS01B buffer. Previous experiments had demonstrated the need to estimate the stability of the formulation in the adjuvant buffer from the start and the experiments described in this report were performed as such.
    Experimental procedure
    Preparation of formulations Two types of formulations have been made. The first type of formulation is illustrated in Figure 1. MAG-Tn3 and CpG7909 are formulated separately and then combined. Excipient A is added to a 5% solution of sucrose in Water for Injection (Thermo-Fisher) at varying concentrations as shown in Table 1, and then magnetically stirred for 5 minutes at 150 rpm. min. MAG-Tn3 obtained from Lonza Braine is then added to the solution at a concentration of 2500 μg / ml for a final dose of 500 μg. This solution is stirred magnetically for 5 minutes at 150 rpm. In a separate container, the excipient B is added to a 5% sucrose solution in water for injection and stirred magnetically for 5 minutes at 150 rpm. CpG7909 (Agilent) is then added to this solution at a concentration of 2100 μρ / ιηΐ. The solution is then stirred magnetically for 5 minutes at 150 rpm. The two solutions, the mixture of MAG-Tn3 and the CpG mixture, are then combined in a ratio of 1/1 and then magnetically stirred for 5 minutes at 150 rpm. This formulation is then diluted 1.25 times in a solution of 50 mM Na 2 HPO 4 / KH 2 PO 4, 150 mM NaCl pH 6.1 (buffer AS01B).
    The formulations are then incubated for twenty-four hours at 4 ° C before being analyzed.
    Table 1
    Buffer compositions tested using the separate mixing method shown in Figure 1
    The second method used for the formulation was a standard flowchart (Figure 2). All excipients, see Table 2 for listing, are added to a 5% solution of sucrose in water for injection at varying concentrations. CpG7909 is then added to the solution at a concentration of 1050 μg / ml. The solution was then stirred magnetically for 5 minutes at 150 rpm. MAG-Tn3 is then added to the solutions at a concentration of 1250 μρ / ιηΐ for a final dose of 500 μg. The solutions are then stirred magnetically for a further 5 minutes at 150 rpm. The formulations are then diluted 1.25 times in a solution of 50 mM Na2HPO4 / KH2PC> 4, 150 mM NaCl pH 6.1. All formulations were then incubated for twenty-four hours at 4 ° C before being analyzed.
    Table 2
    List of excipients formulated in the standard flowchart.
    The concentrations indicated are the concentrations found in the final reconstituted container
    All samples were first visually inspected. If any precipitation or opacity of the solution was noted, no further analysis was performed. If the formulation was translucent, additional assays were performed such as BCA, HPLC-SEC, and SDS-PAGE techniques. A BCA test was performed to estimate the MAG-Tn3 content in the formulations. The protocol and classic Pierce reagents were used. Exclusion chromatography was performed using a Waters 2996 HPLC instrument equipped with a fluorescence detector (Waters) to estimate the aggregation profiles of the resulting formulations using a TSKgel G3000PWx1 column (Tosoh Bioscience LLC) and one phase. mobile 200 mM NaCl (EMD). SDS-PAGE analysis was performed using 4-12% Bis-Tris gels (Invitrogen) and MES migration buffer (Invitrogen). The gels were stained using SilverExpress or SilverQuest from Invitrogen. Centrifuged and non-centrifuged samples were gel run to estimate the presence of precipitate in the formulations. Centrifugation was carried out for 15 minutes at 18,000 g. The supernatant was extracted, after which the pellet was resuspended in IX LDS sample buffer (Invitrogen) and both fractions were run on gels. PH (Orion) and visual inspection were also performed.
    Most of the formulations were unsuccessful and the excipient used could be excluded based on visual inspection, often without starting the 24 hour incubation. The results of the visual appearance analysis can be found in Table 3.
    Table 3
    Table summarizing the results of visual appearance and turbidity. Samples that precipitated were not further tested. PPT: precipitation.
    For those formulations that did not precipitate, the analyzes were performed after the 24 hour incubation at 4 ° C. SDS-PAGE results indicated that although visual inspection precipitation was not observed, most of the formulations had slightly precipitated as indicated in Figure 3 by the arrows. Although one band is present in the pellet fraction, there does not appear to be enough material to observe a corresponding decrease in band intensity in the supernatant fractions.
    What is potentially more disturbing is surrounded by a dotted or dotted line, as this indicates an increase in the intensity of the degradation band that is only slightly present in the control. 10 mM glutamic acid with either 10 mM lysine or 10 mM arginine appear to have a similar band intensity of the degradation band compared to the control. This may be due indirectly to the pH, since these two formulations have a pH of approximately 8, while the other non-surfactant formulations have a very high pH greater than 9. This is further confirmed when both formulations of tris-maleate exhibit barely a degradation band, whereas the high pH tris formulation has a rather intense and well-defined degradation band. See Figure 4.
    The results of the BCA test to determine the MAG-Tn3 content were not promising, see Table 4. It should be noted that the BCA test was not optimized for each buffer system used. Despite this, useful data can be extracted. It is interesting to note that the two formulations that have the lowest loss of MAG-Tn3 content, with the exception of the Empigen formulation, are 10 mM glutamic acid with either 50 mM arginine or
    50 mM lysine. Both of these formulations have pHs of approximately 9.5 and intense degradation bands by SDS-PAGE. The tris-maleate formulations, although somewhat promising by SDS-PAGE, are not promising by the BCA test. Losses of approximately 50% are observed for these two formulations.
    Table 4 Results of MAG-Tn3 antigen content by BCA and HPLC-SEC techniques. The loss percentage is based on a theoretical MAG-Tn3 concentration of 826 μρ / ιηΐ. The concentration of MAG-Tn3 targeted in these formulations was 500 μρ / άοεθ or 1000 μρ / πιΐ based on the mass of the purified bulk used and the reconstitution volume. It was later discovered that the percentage of glycopeptide content should be used in the determination of the concentration in order to take into account the water content and the counter-ion content. For this lot of MAG-Tn3, the glycopeptide content was 82.6%.
    Concentration of MAG-Tn3% of monomer
    Excipient and concentrations by BCA (pg / ml)
    - by HPLC-SEC
    Total% of loss
    7 mM glutamic acid + 20 mM arginine 542.4 34.3 100 1.0% w / v Empigen 957.9 0.0 88.6 10 mM glutamic acid -10 mM lysine 507.3 38.6 100 10 mM glutamic acid - 50 mM lysine 746.2 9.7 100 50 mM glutamic acid - 50 mM lysine 551.9 33.2 100 10 mM glutamic acid -10 mM d arginine 454.7 45.0 100 10 mM glutamic acid - 50 mM arginine 808.7 2.1 100 50 mM glutamic acid - 50 mM arginine 537.7 34.9 100 50 mM Tris -10 mM Maleate 406.8 50.8-75 mM Tris -10 mM Maleate 433.5 47.5-
    The Empigen formulation, although low in pH and showing decent recoveries, shows a large aggregate of high molecular weight on its size exclusion chromatogram (data not shown). This aggregate represents approximately 11% of the area of the peak.
    Many formulations have been tried in an effort to solubilize MAG-Tn3 and CpG7909, however none have been totally effective. MAG-Tn3 appears to be the most soluble at high pH, however pHs greater than 8.5 are known to cleave sugars. Since MAG-Tn3 is a glycopeptide with the sugar Tn being the antigenic part, high pHs should be avoided. At a higher pH, there is an increase in the degradation band by SDS-PAGE, although the identity of this band still needs to be determined, it can be deglycosylated MAG-Tn3 or MAG.
    It is interesting to note that when equal concentrations of anionic and cationic buffers are used, they exhibit the same MAG-Tn3 loss range, 38.6 and 33.2% for the 10 and 50 mM glutamic acid formulations. and lysine. The loss of protein is much lower, 9.7%, when an excess of cationic buffer, in this case lysine, is used. A similar trend is observed for combinations of glutamic acid - arginine. One possible reason for the instabilities of the formulations may be the presence of competing ions. If glutamic acid interacts with arginine or lysine, it will then reduce the amount of arginine or free lysine in the interacting solution and stabilize CpG and prevent coprecipitation with MAG-Tn3. Future experiences will explore this possibility.
    Example 2 - Histidine against arginine. Determination of a buffer system at a lower target dose
    The target dose for the MAG-Tn3 antigen was set at 500 μg / με. In the presence of immunostimulant CpG7909, MAG-Tn3 antigen instantly coprecipitates. A multitude of buffer systems have been tried in an effort to solubilize this antigen-immunostimulatory combination, however none has been adequate. However, histidine and arginine were the most promising buffers among the systems explored. In this report, the experiments performed to determine which buffer system will work better at a lower dose will be described. The essential results obtained from this experiment were that the antigen-immunostimulant combination could be formulated as a soluble solution, however, the targeted antigen dose would have to be reconsidered. The MAG-Tn3 antigen had to be formulated at 500 μg / dose in the presence of immunostimulant CpG7909 at a concentration of 840 μρ / πιΐ in the form of colyophilization. A compatibility study of the buffers was carried out in a previous experiment, in which it was clearly demonstrated that MAG-Tn3 was incompatible with CpG7909 because the solution precipitated after the addition of MAG-Tn3 to the CpG solution. MAG-Tn3 has a theoretical pI between 9.8 and 10; therefore, it is therefore very positively charged at a lower pH. In addition, CpG has 23 negative charges at a lower pH. Therefore, when the two components are combined, co-precipitation occurs. Many buffer systems have been tried in an attempt to solve this, arginine and histidine seemed to provide some help against precipitation, but not completely. The purpose of this article is to describe the experiments carried out with histidine and arginine to help solubilize the MAG-Tn3 antigen in the presence of the immunostimulant CpG7909.
    In the experiment in this report, various concentrations of arginine and histidine were screened with the dose of MAG-Tn3 fixed at a median dose amount of 100 μg and the stability of these samples was then monitored.
    Experimental procedure
    Preparation of the formulations: arginine (Sigma-
    Aldrich) or histidine (Sigma-Aldrich) was added to a 5% solution of sucrose in water for injection (Thermo-Fisher) at concentrations of 15.2, 31.3, 62.5 , and 125 mM. CpG7909 (Agilent) was then added to the solution at a concentration of 1050 μρ / ιηΐ. The solution was then stirred magnetically for 5 minutes at 150 rpm. The MAG-Tn3 obtained from Lonza Braine was then added to the solutions at a concentration of 250 μρ / ιηΐ for a final dose of 100 μρ. The solutions were then stirred magnetically for a further 5 minutes at 150 rpm. The formulations were then diluted 1.25 times in a solution of 50 mM Na 2 HPO 4 / KH 2 PC 4, 150 mM NaCl pH 6.1. All formulations were then incubated for twenty-four hours at 4 ° C before being analyzed.
    Analyzes: RP-HPLC was performed to estimate the content of MAG-TN3 in the formulations before and after filtration with a 0.2 μη syringe filter. A HPLC Waters 2996 instrument equipped with UV detection was used with a Poros R 1/10 column from Applied Biosciences and a gradient from 0 to 100% acetonitrile in 0.1% trifluoroacetic acid. Exclusion chromatography was performed using a Waters 2996 HPLC instrument equipped with a fluorescence detector (Waters) to estimate the aggregation profiles of the resulting formulations using a TSKgel G3000PWx1 column (Tosoh Bioscience LLC) and one phase. mobile 200 mM NaCl. SDS-PAGE analysis was performed using 4 to 12% Bis-Tris gels (Invitrogen) and the MES migration buffer (Invitrogen). The gels were colored using SilverQuest's
    Invitrogen. Centrifuged and non-centrifuged samples were gel run to estimate the presence of precipitate in the formulations. Centrifugation was carried out for 15 minutes at 18,000 g. The supernatant was extracted, after which the pellet was resuspended in IX LDS sample buffer (Invitrogen) and both fractions were run on gels. PH (Orion) and visual inspection were also performed.
    All formulations were translucent and particle free after storage at 4 ° C. However after the 24 hour incubation, histidine solutions were all found slightly turbid to visual inspection. The pH readings, Table 5, did not provide any information regarding the stability of the product; however, it should be noted that histidine formulations have a narrower pH range than arginine formulations with the same concentrations.
    Table 5 pH of the formulations. PH readings were taken for all solutions. _PH_ _Arginine_Histidine_ 12.5 mM 8.4 6.7 25 mM 9.4 6.9 50 mM 9.8 7.1 _100 mM_10.1_7_13_
    The results of SDS-PAGE, seen in Figure 5, confirm the results observed visually. The histidine formulations all contain slight bands in the pelleted fractions, whereas the arginine formulations do not contain any.
    HPLC-SEC results did not provide additional data. All formulations were found to be monomeric and no significant lag in retention time was observed; thus, suggesting that the MAG-TN3 that remained soluble was in monomeric form.
    Table 6
    MAG-Tn3 antigen content. The MAG-Tn3 antigen content was determined by RP-HPLC before and after filtration with a 0.2 μιη syringe filter to estimate the content of insoluble aggregates.
    Concentration of MAG-Tn3 by RP-HPLC (μg / ml)
    Arginine Histidine
    After% of After% of
    Total Total Filtration Recovery Filtration Recovery
    12.5 mM 202.9 Ï88J 92J 209.3 138.4 66 / I 25 mM 209.1 183.2 87.6 197.6 130.7 66.2 50 mM 207.9 184.1 88.5 198 , 4,131.5 66.3 100 mM 204.9 197.4 96.3 202.1 131.9 65.3
    The RP-HPLC results, observed in Table 6, confirmed the results obtained by SDS-PAGE. Histidine formulations all show an approximate 33% loss in filtration as a result of insoluble aggregates. Due to the significant loss of MAG-Tn3 content with histidine formulations, arginine was chosen as the buffer system of choice. Results
    Both histidine and arginine buffer systems help to solubilize MAG-Tn3 in the presence of the CpG7909 immunostimulant. The cationic nature of these buffer systems helps to stabilize the anionic CpG, preventing it from coprecipitating with the MAG-Tn3 antigen. The lower pKa of histidine will make it a more favorable buffer because it will produce formulations with a lower pH; however, it is not as effective as arginine in solubilizing the two main components, as demonstrated by the 33% loss of antigen content in the RP-HPLC assay.
    The side chain of arginine has a pKa of 12.48 making the pH of the final solutions rather high, between pH 8 and 10. The long-term stability of MAG-Tn3 in this buffer system can be hindered because it is a glycopeptide and a high pH promotes deglycosylation. An additional buffer component will need to be added to the formulation in order to lower the pH in a range that will be more favorable with respect to the stability of the antigen.
    The choice of an additional buffer component will be difficult as observed in Example 1. It would appear that the presence of an anionic buffer adds a competitive ion to the cationic buffer system, in this case arginine, releasing the CpG in this way so that it can in turn coprecipitate with the MAG-Tn3. An ideal candidate for an anionic buffer would be a buffer that can lower the pH below 8.5, while not competing with arginine or an anionic buffer that would have more affinity for MAG-Tn3. that CpG does not present for the antigen.
    Example 3 Concentrations of L-Arginine L-Arginine and Hydrochloride in the MAG-Tn3 Vaccine Formulation
    The glycopeptide MAG-Tn3 can be formulated in a soluble vaccine with the immunostimulant CpG7909 at a dose of 300 μρ / ml in an L-arginine buffer system. Previous experiments have shown that L-arginine concentrations between 12.5 and 100 mM were sufficient to solubilize the vaccine formulation. This report will detail the experiments performed to determine the exact concentrations of Larginine and L-arginine monohydrochloride used in the vaccine formula of MAG-Tn3.
    The vaccine formulation of MAG-Tn3 was initially targeted for a dose of 500 μρ in a 500 μΐ injection volume containing 420 μρ of immunostimulant CpG7909. This formulation was not stable and resulted in coprecipitation of the immunostimulant and the antigen. The vaccine formulation was made soluble with the use of L-arginine in combination with a lowering of the targeted dose to 300 μρ of MAG-Tn3. It has been shown in previous experiments that L-arginine monohydrochloride was effective in lowering the pH of the formulation to 8.5 while maintaining a soluble formulation. The need to maintain the pH below 8.5 is due to the potential deglycosylation of the Tn sugar group from the molecule. Tn sugar is the antigenic part of the molecule, its loss would have a significant impact on immunogenicity. The purpose of this report is to describe the experiments performed to optimize L-arginine and L-arginine monohydrochloride concentrations for maximum vaccine stability. L-arginine concentrations of 12.5 to 40 mM were tested with varying concentrations of L-arginine monohydrochloride to maintain a pH around 8.5. Once the L-arginine concentration was established, the concentrations of L-arginine monohydrochloride were screened to determine the optimum pH ensuring maximum stability of the vaccine formulation. In both cases, the lowest concentration that provides the best stability will be chosen as the concentration of choice.
    Experimental procedures
    Preparation of Formulations: Using 500 mM L-arginine stock solutions (EMD) and 1 M L-arginine monohydrochloride (Sigma Aldrich), formulations were made by adding 15.6 to 40 mM L-arginine arginine and 60 to 140 mM L-arginine monohydrochloride to a 5% sucrose (EMD) solution in water for injection (Thermo-Fisher) for the first part of the experiment in which L-arginine was been determined. In the following experiment, 25 mM L-arginine and 125 to 375 mM L-arginine monohydrochloride were added to a 5% sucrose solution in water for injection. CpG7909 (Agilent) was then added to the solution at a concentration of 1050 μρ / ιηΐ. The solution was then magnetically stirred for 5 minutes at 150 rpm. The MAG-Tn3 obtained from Lonza Braine was then added to the solutions at a concentration of 750 μρ / ιηΐ. The solutions were then stirred magnetically for a further 5 minutes at 150 rpm. The formulations were then diluted 1.25 times in a solution of 50 mM Na2HPC> 4 / KH2PO4, 150 mM NaCl pH 6.1. All formulations were then incubated for twenty-four hours at 4 ° C before being analyzed. Chemical agents were provided by Sigma-Aldrich.
    Analyzes: RP-HPLC was performed to estimate the content of MAG-Tn3 in the formulations before and after filtration with a 0.2 μπι syringe filter. A Waters 2996 HPLC instrument equipped with UV detection was used with a Poros R 1/10 column from Applied Biosciences and a gradient from 0 to 100% acetonitrile in 0.1% trifluoroacetic acid. Exclusion chromatography was performed using a Waters 2996 HPLC instrument equipped with a fluorescence detector (Waters) to estimate the aggregation profiles of the resulting formulations using a TSKgel G3000PWx1 column (Tosoh Bioscience LLC) and a mobile phase. 200 mM NaCl. SDS-PAGE analysis was performed using 4-12% Bis-Tris (Invitrogen) gels and MES (Invitrogen) migration buffer. The gels were stained using SilverQuest from Invitrogen. Centrifuged and non-centrifuged samples were gel run to estimate the presence of precipitate in the formulations. Centrifugation was carried out for 15 minutes at 18,000 g. The supernatant was extracted, after which the pellet was resuspended in IX LDS sample buffer (Invitrogen) and both fractions were run on gels. Turbidity (HACH), pH (Orion), and visual inspection were also performed.
    All formulations were found translucent and particle free after incubation for 24 hours at 4 ° C by visual analysis.
    SDS-PAGE results, viewed in Figure 6, indicate that all formulations of 12.5 to 30 mM Larginine are stable, with the exception of the 15 mM formulation of L-arginine which has a slightly higher band intense in its base fraction.
    The turbidity and pH results are similar between the formulations and no significant difference was noted, as can be seen below in Table 7.
    Table 7 -
    Screening of L-arginine. A summary of the results of the screening of L-arginine is proposed.
    Concentration of MAG-Tn3 by RP-%
    Concentration "
    HPLC turbidity (pg / ml) L-arginine monomer pH - (NTU) After% of HPLC- (mM) Total
    filtration recovery SEC 12 ^ 5 0.465 8 ^ 0 736.9 583.6 79 ^ 2 94 ~ 4 15.0 0.836 8.2 871.0 782.8 89.9 94.0 17.5 0.442 8.2 782.6 804.4 102.8 94.3 20.0 0.417 8.3 755.3 792.0 104.9 94.4 22.5 0.468 8.4 824.2 826.1 100.2 94.7 25.0 0.488 8.4 783.9 784, 5 100.1 94.9 27.5 0.558 8.5 849.6 781.6 92.0 95.1 30.0 0.439 8.5 933.4 845.8 90.6 95.5 32.5 0.472 8.5 900.8 839 , 7 93.2 95.6 35.0 0.513 8.6 870.2 851.6 97.9 95.5 37.5 0.450 8.6 869.3 896.3 103.1 96.0 40.0 0.509 8.6 868.8 790.9 91.0 95.9
    There is also no significant difference in% monomer observed by HPLC-SEC, all formulations are monomeric as shown in Figure 7, with the main peak eluting at 15.9 minutes. 20 mM L-arginine was selected to screen for L-arginine monohydrochloride concentrations. Bands begin to appear more intensely in the pelleted fractions at 225 mM L-arginine monohydrochloride, as seen in Figure 8.
    The results of the turbidity are very similar between the formulations, as observed in Table 8. The pH also does not show much variation. A pH range of 7.8 to 8.2 is observed.
    Table 8 Summary of Screening of L-arginine monohydrochloride. A summary of the results of the screening of L-arginine monohydrochloride is proposed
    Concentration concentration of MAG-Tn3 by RP-% monohydrochloride Turbidity HPLC (pg / ml) monomer L-arginine (NTU) After% of HPLC-
    total
    (mM) SEC recovery 0.434 8 288 816.2 93J 94 125 125 0.386 8.2 868.0 709.4 81.7 95.3 150 0.394 8.0 776.9 864.4 111 , 3 95.2 175 0.429 8.0 800.2 829.8 103.7 95.3 200 0.367 8.0 914.9 669.1 73.1 95.0 225 0.410 7.9 877.5 752.4 85.7 94.9 250 0.374 7.8 876.7 699.0 79.7 95.2 275 0.339 7.8 792.3 777.1 98.1 95.2 300 0.439 7.8 866.5 839 9 96.9 94.9
    The% recovery of the MAG-Tn3 content after filtration demonstrates more variability. The concentrations of L-arginine monohydrochloride of 125 mM and 200 mM to 250 mM show a significant recovery loss of 30 to 15% indicating the presence of insoluble aggregates. The 20% recovery loss at 125 mM Larginine monohydrochloride is potentially erroneous, since the recovery at 100 mM is 93.7%. The% recovery improves again at 275 mM and 300 mM L-arginine monohydrochloride, an explanation for this needs to be further understood.
    The remaining soluble portion of the L-arginine monohydrochloride formulations is monomeric. Aggregation profiles, as shown in Figure 9, indicate a monomer population.
    Discussion
    L-arginine concentrations of 17.5 mM to 40 mM were found to be stable. Both 12.5 and 15 mM Larginine show a 10 to 20% loss of MAG-Tn3 recovery by RP-HPLC, suggesting the presence of insoluble aggregates. 20 mM L-arginine was chosen as the buffer concentration since the stability of the formulation between 15 and 17.5 mM is uncertain as these formulations have not been tested. 20 mM L-arginine allows some maneuverability, however, if ± 20% specifications are applied to 20 mM L-arginine, the acceptable range of concentrations will be 16-24 mM. The stability of 16 mM will have to be estimated because 15 mM shows a loss of MAG-Tn3 content after filtration of 10%.
    Screening of L-arginine monohydrochloride provided interesting results. The pH did not shift much despite a wide range of L-arginine monohydrochloride used, however, all pHs were below 8.5, which is the pH to be avoided for its sugar deglycosylation potential Tn from the MAG-Tn3. 150 mM L-arginine monohydrochloride is sufficient to lower the pH to 8.0 and maintain a stable formulation. There is no loss after filtration, no band present in the pellet fraction by SDS-PAGE and the aggregation profile is monomeric for this formulation. Acceptance criteria for excipient concentrations upon submission to a release assay are ± 20%, which will place the range for L-arginine monohydrochloride between 120 mM and 180 mM. The lower value of this would appear to be in a range of potential instability because the% recovery of MAG-Tn3 at 125 mM is 81.7%. This low value may be abnormal, since the recovery at 100 mM L-arginine monohydrochloride is 93.7%. Analyzes will have to be performed to confirm the stability at 120 mM L-arginine monohydrochloride.
    The final concentration of buffer for the formulation of 300 μρ / dose of MAG-Tn3 with CpG7909 is 20 mM Larginine and 150 mM L-arginine monohydrochloride.
    Example 4 - Determination of a Maximum Dose for MAG-Tn3 Antigen in an Arginine Buffer System
    The target dose for the MAG-Tn3 antigen was set at 500 μg / dose. In the presence of immunostimulant CpG7909, the MAG-Tn3 antigen instantly coprecipits at this concentration. A soluble formulation is possible at a lower dose of 100 μρ MAG-Tn3 / dose in an arginine buffer system; however, a higher dose would be preferable. In this report, the experiments carried out to determine the maximum dose of MAG-Tn3 will be described.
    The vaccine formulation of MAG-Tn3 was initially targeted for a dose of 500 μρ in an injection volume of 500 μΐ containing 420 μρ of the immunostimulant CpG7909. This formulation was not stable and resulted in coprecipitation of the immunostimulant and the antigen. Co-precipitation was slightly mitigated with the addition of the histidine or arginine buffer systems.
    In the previous experiment, a soluble (non-precipitated) formulation was obtained by lowering the dose of MAG-Tn3 antigen from 500 μρ / dose to 100 μρ / dose and using arginine as a buffer system . However, a higher dose would be preferable. The purpose of this article is to describe experiments performed to determine the maximum dose of glycopeptide antigen, MAG-Tn3, in an arginine buffer system. The arginine buffer system used in this report is a mixture of L-arginine and L-arginine monohydrochloride. L-arginine monohydrochloride is added in an attempt to lower the pH to a more favorable range for product stability and injectability. The initial experiment screened a large dose range of MAG-Tn3 from 200 μg / ml to 900 μg / dose. Once the upper limit was established, a smaller range of doses of MAG-Tn3 was screened from 800 μρ / ιηΐ to 900 μρ / πιΐ and finally a dose was chosen.
    Experimental procedures
    Preparation of Formulations: Using stock solutions of 500 mM L-arginine and 1 M L-arginine monohydrochloride, formulations were made by adding 31.3 mM L-arginine and 187.5 mM monohydrochloride. Larginine to a solution of 5% sucrose in water for injection (Thermo-Fisher). CpG7909 (Agilent) is then added to the solution at a concentration of 1050 μρ / πιΐ. The solution was then stirred magnetically for 5 minutes at 150 rpm. MAG-Tn3 obtained from Lonza Braine was then added to the solutions at concentrations in the range 250 to 1125 μg / ml. The solutions are then stirred magnetically for a further 5 minutes at 150 rpm. The formulations are then diluted 1.25 times in a solution of 50 mM Na2HPC> 4 / KH2PO4, 150 mM NaCl pH 6.1. All formulations were then incubated for twenty-four hours at 4 ° C before being analyzed. Chemical agents were provided by Sigma-Aldrich.
    Analyzes: RP-HPLC was performed to estimate the content of MAG-Tn3 in the formulations before and after filtration with a 0.2 μιη syringe filter. A HPLC Waters 2996 instrument equipped with UV detection was used with a Poros R 1/10 column from Applied Biosciences and a gradient from 0 to 100% acetonitrile in 0.1% trifluoroacetic acid. Exclusion chromatography was performed using a Waters 2996 HPLC instrument equipped with a fluorescence detector (Waters) to estimate the aggregation profiles of the resulting formulations using a TSKgel G3000PWx1 column (Tosoh Bioscience LLC) and a mobile phase. 200 mM NaCl. SDS-PAGE analysis was performed using 4-12% Bis-Tris (Invitrogen) gels and MES (Invitrogen) migration buffer. The gels were stained using SilverQuest from Invitrogen. Centrifuged and non-centrifuged samples were gel run to estimate the presence of precipitate in the formulations. Centrifugation was carried out for 15 minutes at 18,000 g. The supernatant was extracted, after which the pellet was resuspended in LOS IX sample buffer (Invitrogen) and both fractions were run on gels. Turbidity (HACH), pH (Orion), and visual inspection were also performed.
    All formulations were found translucent and particle free after incubation for 24 hours at 4 ° C. It has been found that the pH and turbidity results are similar between the formulations; no significant difference was noted, as can be seen below in Table 9.
    Table 9
    Turbidity and pH. Turbidity and pH results from a screening of 200 to 900 μg / ml MAG-Tn3 MAG-Tn3 (μg / ml) 200 300 400 500 600 700 800 900
    Turbidity (NTU) 0.389 0.433 0.421 0.528 0.347 0.402 0.430 0.343 pH 8.5 8.5 8.5 8.5 8.5 8.5 8.5 8.5
    The SDS-PAGE results, viewed in Figure 10, indicate a stable formulation up to a concentration of 900 μg / ml where there is the presence of a very slight band in the pellet fraction. However, this is not detected as an insoluble aggregate because the% recovery of the filtered versus unfiltered sample is 100.0% by RP-HPLC, see Table 10.
    Table 10
    MAG-Tn3 content. MAG-Tn3 antigen content determined by RP-HPLC before and after filtration with a 0.2 μm syringe filter to estimate the content of insoluble aggregates
    Concentration of MAG-Tn3 by RP-HPLC (μg / ml)
    Targeted concentration of _% MAG-Tn3 (pg / ml) Total After filtration recovery 2ÖÖ 214.1 206.5 96 ^ 5 300 327.5 294.2 89.8 400 423.7 408.1 96.3 500 528 , 1,520.7 98.6 600 655.6 621.9 94.9 700 757.7 689.2 91.0 800 844.7 808.4 95.7 900 1007.2 963.7 95.7
    Exclusion chromatography indicated no change in the aggregation pattern for all tested concentrations, as there was no lag in the observed retention time, or the appearance of peaks at longer retention times. short, indicating the presence of aggregates, as can be seen in Figure 11.
    Screening of narrower doses was carried out between 800 and 900 μg / ml, the resulting gel can be visualized in FIG. 12. Two slight bands can be observed in all the fractions of the pellets including the control (purified bulk of Tn3); however, the bands are slightly more intense at doses of 825, 850, 875, 900 μg / ml of MAG-Tn3. The presence of the bands in the pelleted fractions is not detected as insoluble aggregates since the% recovery of filtered versus unfiltered samples is 100 ± 10% (Table 11). There is also no observation of any soluble aggregates in the form of single monomer peaks by exclusion chromatography.
    Table 11
    Dose range 800 to 900 μg / ml. A summary of dose range results from 800 to 900 μg / ml is proposed
    Concentration Concentration of MAG-Tn3 (pg / ml)
    Turbidity% of monomer
    Targeted MAG-pH ΑηΦ *% Hp
    (NTU) Total after HPLC-SEC
    Tn3 (pg / ml) filtration recovery
    8,074,474 1,793.9 857.6 108.0 95J 825 0.382 8.5 870.9 851.3 97.8 100.0 850 0.392 8.5 1044.5 991.3 94.9 100.0 875 0.395 8.5 960.2 946.4 98.6 100.0 900 0.383 8.5 968.7 973.2 100.5 100.0 _ The MAG-Tn3 antigen appears to be soluble in the L-arginine buffer system - L-arginine monohydrochloride up to a concentration of 900 μg / ml in the final reconstituted vaccine or 450 μg / dose. Since the stability of MAG-Tn3 in the presence of CpG7909 is precarious as has been demonstrated by the multitude of attempts to solubilize both ingredients, a lower dose has been chosen.
    During stability and product release analysis, the acceptance criteria for the antigen content are set at 100 ± 20%. The extreme value of 120% must also be a soluble formulation, therefore if the upper limit of the solubility of MAG-Tn3 is 900 μς / ΐαΐ, the centered concentration of MAG-Tn3 will then be 7 50 μς / ιηΐ.
    The dilution factor observed between the formulated bulk product and the reconstituted lyophilized cake should also be considered. 500 μl of formulated bulk are lyophilized and reconstituted in a volume of 625 μΐ, resulting in a dilution factor of 1.25. This must also be added to the calculation of the dose. If 750 μg / ml represents the maximum concentration that can be obtained, it will concern the final bulk, the concentration of the final container will then be 600 μρ / πιΐ for a dose of 300 μς.
    The maximum dose of MAG-Tn3 that can be formulated as a colyophilized product with the immunostimulant CpG7909 is 300 μg in an arginine buffer system. The arginine buffer system in these experiments was chosen based on pH; however, optimization of these components will be necessary.
    Example 5 Screening of immunostimulatory doses in the MAG-Tn3 vaccine formulation
    The glycopeptide MAG-Tn3 can be formulated in a soluble vaccine with the immunostimulant CpG7909 at a dose of 300 μl of MAG-Tn3 and 380 μρ of CpG7909 / ml in an L-arginine buffer system (for the purposes of this invention). discussion, the liquid volume of a dose is defined as 500 μΐ). A range of possible CpG concentrations within a 100 ± 20% acceptance criterion was investigated in this experiment to determine if MAG-Tn3 remains soluble in a CpG7909 dose range.
    The amount of CpG7909 was reduced from 420 μ ρΞ to 380 based on a standard quantified by NMR. Using the acceptance criteria of 100 + 20%, a range of CpG doses from 300 to 460 μςΜοΞθ was studied. The purpose of this report is to describe the experiment conducted to ensure that the formulation has remained stable. Formulations containing 180 to 420 μg of CpG / dose were screened for stability.
    Experimental procedures
    Preparation of Formulations: Using stock solutions of 250 mM L-arginine (EMD) and 1875 mM L-arginine monohydrochloride (Sigma Aldrich), formulations were made by adding 25 mM Larginine - 187.5 mM of L-arginine monohydrochloride to a solution of 5% sucrose (EMD) in water for injection (Thermo-Fisher) and 0.1% Polysorbate 80 (NOF). CpG7909 (Agilent) was then added to the solution at a concentration of 365 to 838 μρ / πιΐ. The solution was then stirred magnetically for 5 minutes at 150 rpm. The MAG-Tn3 obtained from Lonza Braine was then added to the solutions at a concentration of 750 μρ / ιηΐ. The solutions were then stirred magnetically for a further 5 minutes at 150 rpm. The formulations were then diluted 1.25 times in a solution of 50 mM Na2HPC> 4 / KH2PO4, 150 mM NaCl pH 6.1. All formulations were then placed in the HPLC autosampler at 25 ° C for T0, 4 hour and 24 hour injections. These formulations are considered final containers reconstituted from standards because they have not passed through the lyophilization process.
    Analyzes: Exclusion chromatography was performed using a Waters 2996 HPLC instrument equipped with a fluorescence detector (Waters) to estimate the aggregation profiles of the resulting formulations using a guard column and analytical TSKgel Supermultipore PW- N (Tosoh Bioscience LLC) with a flow rate of 0.5 ml / min and a mobile phase of 20 mM L-arginine, 150 mM L-arginine-HCl, 0.08% polysorbate 80, 150 mM NaCl, 10 mM Na / K 2 phosphate buffer pH 6.1. Fluorescence detection was performed with an excitation wavelength of 270 nm and an emission wavelength of 318 nm. Results
    Exclusion chromatography indicated no change in aggregation pattern for all CpG 7909 concentrations tested, as there was no lag in the retention time observed for the main peak of MAG-Tn3 monomer at a retention time of 8.573 minutes. There is no change in peak size at shorter retention times, indicating the slight presence of aggregates compared to the various concentrations of CpG7909 as can be seen in Figure 13. 350 and 230 μg CpG7909 / dose were also tested and found to have a similar profile, the results are not presented. The incubation of the samples for 4 and 24 hours at 25 ° C causes a change in the aggregation pattern as can be seen in Figure 14. The peak at 5.6 minutes, corresponding to aggregates, increases in peak area compared to the time spent at 25 ° C.
    This phenomenon is observed at all doses of CpG7909 tested as can be seen in FIG. 15. 350 and 230 μg of CpG7909 / dose are not included in FIG. 15, but have the same profile. The peak areas of both aggregate peak and monomer peak (8.55 minutes) remain relatively constant, CV% is less than 10%, with increasing concentrations of CpG7909, as can be seen in table 12.
    Table 12
    Comparison of peak areas of MAG-Tn3 monomer and aggregates at various dose concentrations of CpG 7909 Concentration of
    Aggregate Monomer
    CpG 4h to 24h to 4h to 24h to
    (pg / dose) TO TO
    25 ° C 25 ° C 25 ° C 25 ° C 420 4389470 4312017 4170588 52262 105071 251364 350 4511361 4430311 4322682 47834 106801 256292 270 4611544 4503391 4389977 46794 112739 250982 230 4700524 4569933 4449942 44161 115236 252104 180 4882667 4719013 4601093 44244 126648 267041
    And! 187412 152334 158727 3319 8547 6761 CV% 4.06 3.38 3.62 7.05 7.54 2.65
    The formulation containing 20 mM L-arginine and 150 mM L-arginine monohydrochloride creates a suitable matrix for the MAG-Tn3 antigen and the CpG7909 immunostimulant at concentrations in the range of 180 to 420 μg per dose. The bulk concentration of CpG7 909 is determined using a standard quantified by NMR. Although an increase in aggregates is observed during incubation at 25 ° C, these aggregates are present in the same amounts regardless of the concentration of CpG7909, suggesting that the aggregates are due to the instability of the antigen as opposed to at an incompatibility with the concentration of CpG7909. The upper limit of potential concentrations of CpG7909 was not tested in this experiment; however, the observed trend indicates that a formulation containing 460 μl / μl of CpG7909 will be stable.
    Example 6 - pH Study
    The pH values calculated for various arginine and arginine hydrochloride mixtures were compared with those determined with a pH meter (Table 13).
    Table 13 pH calculated versus observed
    权利要求:
    Claims (42)
    [1]
    A substantially stable vaccine composition comprising: (a) arginine; (b) a counterion; (c) a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and (d) a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge; said composition characterized in that when said composition comprises water (i) said first and second immunogenic molecules are substantially stable; and (ii) the pH of the resulting solution is less than 8.5.
    [2]
    2. Composition according to claim 1, wherein said composition characterized in that when said composition comprises water, the pH is within a range selected from the group consisting of: (a) a range where (i) the upper limit is less than 8.5; less than 8.4; less than 8.3; less than 8.2; less than 8.1; less than 8.0; less than 7.9; less than 7.8; less than 7.7; less than 7.6; or less than 7.5; and (ii) the lower limit is greater than 7.4; greater than 7.5; greater than 7.6; greater than 7.7; greater than 7.8; greater than 7.9; greater than 8.0; greater than 8.1; greater than 8.2; greater than 8.3; or greater than 8.4; (b) a range between 7.4 and 8.5, inclusive; between 7.5 and 8.5, inclusive; between 7.6 and 8.3, inclusive; between 7.7 and 8.3, inclusive; between 7.8 and 8.3, inclusive; between 7.9 and 8.3, inclusive; between 8.0 and 8.3, inclusive; between 8.1 and 8.3, inclusive. (c) a range where the pH is not more than ± 0.2 pH units outside the range of (a) or (b).
    [3]
    A composition according to any one of the preceding claims further characterized in that when said composition comprises water, the arginine comprises the following species: (a)

    Formula V and '

    (b) Form IV.
    [4]
    The composition of claim 3, further characterized in that when said composition comprises water, the concentration of the species of (a) formula V is at least 14 mM, and the molar ratio of the species (a) Formula V on the species of (b) Formula IV is within a range selected from the group consisting of: (a) between 0.091 and 0.200; (b) between 0.032 and 0.323; (c) between 0.041 and 0.323; (d) between 0.051 and 0.256; (e) between 0.064 and 0.256; and (f) between 0.081 and 0.204.
    [5]
    An immunogenic composition according to any one of the preceding claims, wherein the first immunogenic molecule is Mag-Tn3.
    [6]
    The composition of any of the preceding claims, wherein the second immunogenic molecule comprises a CpG oligonucleotide.
    [7]
    The composition of claim 6, wherein the oligonucleotide is selected from the group consisting of: SEQ ID NO: 1; SEQ ID NO: 2; SEQ ID NO: 3; SEQ ID NO: 4; SEQ ID NO: 5; and SEQ ID NO: 6.
    [8]
    8. Composition according to any one of the preceding claims further comprising a cryoprotectant.
    [9]
    The composition of claim 8, wherein the cryoprotectant is selected from the group consisting of sucrose and trehalose.
    [10]
    10. A composition according to any one of the preceding claims, wherein the counterion is chloride.
    [11]
    The composition of claim 10 wherein a portion of the arginine is present as the arginine monohydrochloride species.
    [12]
    12. Composition according to claim 11, wherein the composition is dried, and the ratio arginine / arginine monohydrochloride is 20/150 (mol / mol).
    [13]
    The composition of claim 12 wherein the arginine / arginine monohydrochloride ratio is 1.74 / 15.8 (w / w).
    [14]
    14. Composition according to any one of claims 12 or 13 comprising (i) between 30 and 450 μg of MAG-Tn3, included; (ii) 475 μg CpG 7909 (SEQ ID NO: 4); (iii) 0.87 mg arginine; (iv) 7.9 mg arginine monohydrochloride; (v) 0.216 mg Polysorbate 80; and (vi) 10 mg of sucrose.
    [15]
    15. Composition according to any one of claims 1 to 11, further comprising water.
    [16]
    The composition of claim 15, wherein the first immunogenic molecule comprises MAG-Tn3 and is present at a concentration of less than 900 μg / ml.
    [17]
    17. Composition according to any one of claims 15 or 16, wherein the second immunogenic molecule is a CpG oligonucleotide and the CpG oligonucleotide is present at a concentration between 760 and 1140 μg / ml, inclusive.
    [18]
    18. A composition according to any one of claims 15 to 17, wherein the arginine is present in a concentration of at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, or 40 mM.
    [19]
    19. A composition according to any one of claims 15 to 18, wherein the arginine is present at a concentration of 25 mM.
    [20]
    20. A composition according to any one of claims 15 to 18, wherein the arginine is present at a concentration of 20 mM.
    [21]
    A composition according to any one of claims 15 to 20, wherein the arginine monohydrochloride is present in a concentration of at least 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, or 300 mM.
    [22]
    22. Composition according to any one of claims 15 to 21, wherein the arginine monohydrochloride is present at a concentration of 187.5 mM.
    [23]
    23. Composition according to any one of claims 15 to 22, comprising (i) between 60 and 900 μg / ml of MAG-Tn3, included; (ii) 950 μρ / πιΐ of CpG 7909 (SEQ ID NO: 4); (iii) 25 mM arginine; (iv) 187.5 mM arginine monohydrochloride; (v) 0.108% w / v Polysorbate 80; and (vi) 5% w / v sucrose.
    [24]
    24. Composition according to any one of claims 15 to 21, wherein the arginine monohydrochloride is present at a concentration of 150 mM.
    [25]
    25. Composition according to any one of claims 15 to 21 and 24, comprising (i) between 48 and 72 0 μς / ιτί of MAG-Tn3, inclusive; (i i) 760 μs / μl of CpG 7909 (SEQ ID NO: 4); (iii) 20 mM arginine; (iv) 150 mM arginine monohydrochloride; (v) 0.0864% w / v Polysorbate 80; and (vi) 4% w / v sucrose.
    [26]
    The composition of any one of claims 1 to 11 and 15 to 25, further comprising (a) an adjuvant composition comprising one or more adjuvants, wherein at least one of said adjuvants is selected from the group consisting of MPL and QS21; and (b) an adjuvant composition comprising liposomes and one or more adjuvants, wherein at least one of said adjuvants is selected from the group consisting of MPL and QS21.
    [27]
    27. Composition according to claim 26, comprising (i) between 48 and 720 μρ / ιηΐ of MAG-Tn3, inclusive; (ii) 760 μg / ml of CpG 7909 (SEQ ID NO: 4); (iii) 20 mM arginine; (iv) 150 mM arginine monohydrochloride; (v) 0.0864% w / v Polysorbate 80; and (vi) 4% w / v sucrose; (vii) 150 mM NaCl; (viii) 8mM KH2PO4 and 2mM Na2HPO4; (ix) 50 μl / ml of MPL; (x) 100 μρ / ml of liposomes; and (xi) 100 μρ / ml of QS21.
    [28]
    The process for producing the essentially stable vaccine composition according to any one of claims 1 to 11 and 15 to 27, comprising combining the components comprising: (a) arginine; (b) a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and (c) a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge; wherein one or more of (a) to (c) are combined with a liquid comprising water and wherein the pH of said composition is 8.5 or lower.
    [29]
    The method of claim 28, further comprising a step of adjusting the pH of the arginine by neutralization with a suitable acid.
    [30]
    30. The process for producing the substantially stable vaccine composition according to any one of claims 1 to 11 and 15 to 27, comprising combining the components comprising: (a) arginine; (b) arginine monohydrochloride; (c) a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and (d) a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge; wherein one or more of (a) to (d) are combined with a liquid comprising water and an adjuvant.
    [31]
    A process for producing the essentially stable vaccine composition according to any one of claims 12 to 14, comprising the combination of the components comprising: (a) arginine; (b) arginine monohydrochloride; (c) a first immunogenic molecule comprising a Tn group, wherein the first immunogenic molecule has a net positive charge; and (d) a second immunogenic molecule comprising an oligonucleotide, wherein the second immunogenic molecule has a net negative charge; wherein one or more of (a) to (d) are combined with a liquid comprising water, further comprising a step of drying the composition.
    [32]
    The method of claim 31, wherein the drying step comprises lyophilization.
    [33]
    33. A process for producing a substantially stable vaccine composition comprising the steps of combining the composition of any one of claims 1 to 25 with a liquid comprising water.
    [34]
    A process for producing a substantially stable vaccine composition comprising the steps of combining the composition of any one of claims 1 to 25 with a liquid comprising water, wherein the liquid further comprises an adjuvant composition comprising one or more adjuvants, wherein at least one of said adjuvants is selected from the group consisting of MPL and QS21.
    [35]
    The method of claim 34, wherein the adjuvant composition further comprises liposomes.
    [36]
    36. Composition produced by the process according to any one of claims 28 to 35.
    [37]
    37. A method of treating a patient comprising the steps of administering a composition of claims 1 to 11 and 15 to 27 to a human.
    [38]
    38. Use of arginine monohydrochloride as an additive to stabilize a vaccine composition.
    [39]
    39. A method of inducing an immunogenic response comprising the steps of administering a composition of claims 1 to 11 and 15 to 27 to a human.
    [40]
    40. A composition according to any one of claims 1 to 27 for use in medicine, as for use in inducing an immune response.
    [41]
    41. The composition according to any one of claims 1 to 27, wherein the first immunogenic molecule is Mag-Tn3, for use in the treatment of cancer.
    [42]
    42. A container comprising a composition according to any one of claims 1 to 27 and 36.
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2550271C2|2015-05-10|Immunogenic composition for treatment or prevention of clostridium difficile, method of obtaining thereof and method of inducing immune response to c difficile
    RU2518240C2|2014-06-10|Composition based on hydrophobic agents and method for preparing it |
    CZ20014150A3|2002-05-15|Preparation containing aqueous solution, lyophilized preparation of A beta peptide, process for preparing sterile preparation, prophylaxis and treatment method, method of inducing antibody response and use
    BE1016991A6|2007-11-06|ADJUVANT COMPOSITION COMPRISING ALUMINUM PHOSPHATE AND 3D-MPL
    BE1023213B1|2016-12-21|COMPLEXES FROM CYTOMEGALOVIRUS AND USES THEREOF
    US9603799B2|2017-03-28|Liposomal vaccine adjuvants and methods of making and using same
    BE1024188B1|2017-12-14|DRY COMPOSITION
    BE1024094B1|2017-11-16|VACCINE
    BE1024284A1|2018-01-12|IMMUNOGENIC COMPOSITIONS
    BE1022254B1|2016-03-04|FORMULATION OF SUCROSE VACCINE
    WO2014145839A2|2014-09-18|Liposomal vaccine adjuvants and methods of processing or using same
    US20200383917A1|2020-12-10|Poly|-block-poly | nanocarrier platform for enhanced efficacy of immunosuppressive agents
    Braga et al.2016|Molecular confinement of human amylin in lipidic nanoparticles
    BE1024160B9|2017-12-06|IMMUNOGENIC FORMULATION
    AU2015201233B2|2017-02-23|Pharmaceutical compositions containing clostridium difficile toxoids a and b
    WO2016097618A1|2016-06-23|Use of pll for improving the stability of molecules in solution
    WO2015055733A1|2015-04-23|Therapeutic cancer vaccine based on stress proteins rendered immunogenic
    同族专利:
    公开号 | 公开日
    BR112016002349A2|2017-08-01|
    EP3030258A1|2016-06-15|
    MX2016001694A|2016-05-02|
    AR097188A1|2016-02-24|
    IL243873D0|2016-04-21|
    US20170119864A1|2017-05-04|
    JP2016527291A|2016-09-08|
    CA2920221A1|2015-02-12|
    SG11201600786RA|2016-03-30|
    WO2015018753A1|2015-02-12|
    GB201314248D0|2013-09-25|
    AU2014304668A1|2016-03-24|
    KR20160040705A|2016-04-14|
    CN105592857A|2016-05-18|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    EP2119451A1|2007-03-09|2009-11-18|Otsuka Pharmaceutical Co., Ltd.|Lyophilized preparation comprising influenza vaccine, and method for preparation thereof|
    法律状态:
    2020-05-29| MM| Lapsed because of non-payment of the annual fee|Effective date: 20190831 |
    优先权:
    申请号 | 申请日 | 专利标题
    GBGB1314248.4A|GB201314248D0|2013-08-08|2013-08-08|Saccharide vaccine formulation|
    US13142484|2013-08-08|
    GB13142484|2013-08-08|
    US201361865166P| true| 2013-08-13|2013-08-13|
    [返回顶部]